Dr Paul Catchpole, Value and Access Director, ABPI, said:
"Today's now finalised proposals for the new Cancer Drugs Fund confirm a seemingly reduced level of ambition from NHS England for providing NHS patients in England with access to the latest cancer medicines because the NICE decision making process remains largely unchanged.
Developing the detail of the proposals, including how the new conditional approval and data collection process will actually work in practice, is already underway. The ABPI will work with NICE and NHS England to ensure the new process can be optimised to best support patients get early access to new cancer medicines.
When the new CDF opens for new applications in July there will be a significant backlog of cancer medicines waiting to be evaluated – some for over a year. Prioritising this backlog appropriately, whilst at the same time evaluating cancer medicines already nearing launch will be hugely challenging and resource intensive. The pharmaceutical industry will do its utmost to help.
When the Accelerated Access Review (AAR) – the Government's initiative to help speed up access to medicines and technologies - publishes in April, there will be a further opportunity to consider the UK's ambition to provide patients with access to all new medicines, in a more co-ordinated way. The ABPI will continue to make the case for more substantial changes to be made to the decision making processes for all medicines, including those for cancer."
About the ABPI
The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. We represent companies supplying around 90% of all medicines used by the NHS, and are researching and developing the majority of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome diseases.
The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry, for statutory consultation requirements including the pricing scheme for medicines in the UK.
ABPI Press Office
Telephone during work hours (9am to 5pm Monday to Friday): +44 (0) 20 7747 7147 or +44 (0) 20 7747 1441
Telephone out of hours (5pm to 9am and weekends): +44 (0) 20 7747 1445.